Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $38.8 Million - $56.2 Million
-1,283,073 Reduced 48.11%
1,383,810 $44.7 Million
Q4 2023

Feb 14, 2024

BUY
$31.31 - $44.19 $83.5 Million - $118 Million
2,666,883 New
2,666,883 $112 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $6.5 Million - $10.9 Million
457,467 New
457,467 $8.68 Million
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $6.65 Million - $8.59 Million
-435,751 Closed
0 $0
Q4 2022

Feb 14, 2023

SELL
$6.59 - $17.75 $10.1 Million - $27.2 Million
-1,531,549 Reduced 77.85%
435,751 $7.73 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $7.73 Million - $12.5 Million
1,967,300 New
1,967,300 $11 Million
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $1.55 Million - $2.6 Million
-459,300 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $2.23 Million - $3.87 Million
-441,200 Reduced 49.0%
459,300 $2.53 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $6.6 Million - $8.39 Million
900,500 New
900,500 $7.67 Million
Q2 2021

Aug 16, 2021

SELL
$9.4 - $16.85 $1.77 Million - $3.17 Million
-187,900 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$13.08 - $49.6 $922,140 - $3.5 Million
-70,500 Reduced 27.28%
187,900 $3.01 Million
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $45.6 Million - $66.1 Million
-1,254,866 Reduced 82.92%
258,400 $11.9 Million
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $30.8 Million - $53 Million
1,363,623 Added 911.25%
1,513,266 $53.3 Million
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $1.75 Million - $3.59 Million
126,251 Added 539.72%
149,643 $3.64 Million
Q1 2020

May 15, 2020

BUY
$8.36 - $17.13 $195,557 - $400,704
23,392 New
23,392 $364,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.